Certificate of Analysis and Data Sheet

Source:

Catalog No.
HOR-265

Background:

Octreotide acetate is a longer acting synthetic octapeptide analog of naturally occurring somatostatin. It inhibits the secretion of gastro-entero-pancreatic peptide hormones and the release of growth hormone.

Description :

Synthetic Human Octreotide is a single, non-glycosylated, polypeptide chain containing 8 amino acids, having a molecular mass of 1019.26 Dalton and a molecular formula of C₄₉H₆₆N₁₀O₁₀S₂ .
Octreotide is purified by proprietary chromatographic techniques.

Physical Appearance:

Sterile Filtered White lyophilized (freeze-dried) powder.

Formulation:

Octreotide was lyophilized from a concentrated (1mg/ml) solution with no additives.

Solubility:

It is recommended to reconstitute the lyophilized Octreotide in sterile 18MΩ-cm H2O not less than 100ug/ml, which can then be further diluted to other aqueous solutions.

Stability:

Lyophilized Octreotide although stable at room temperature, should be stored desiccated below 0 C. Reconstituted Octreotide is best stored refrigerated at 4 C.
Please avoid freeze-thaw cycles.

Purity:

Greater than 98.0% as determined by:
(a) Analysis by RP-HPLC.
(b) Anion-exchange FPLC.
(c) Analysis by reducing and non-reducing SDS-PAGE Silver Stained gel.

Amino acid sequence:

The sequence was determined to be H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-L-threoninol

Usage:

Prospec's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.

Latest Publications:

1. Octreotide for treating chylothorax after cardiac surgery.
Tex Heart Inst J 2005;32(3):437-9
2. One-year follow-up study of patients with enterochromaffin-like cell carcinoids after treatment with octreotide long-acting release.
Scand J Gastroenterol 2005 Nov;40(11):1269-74
3. Poor responses to a test dose of subcutaneous octreotide predict the need for adjuvant therapy to achieve 'safe' growth hormone levels.
Pituitary 2004;7(3):139-44
4. Successful long-term treatment with once-daily injection of low-dose octreotide in an aged patient with insulinoma.
Endocr J 2005 Oct;52(5):629-34
5. A case of hyperinsulinemia of undetermined origin, successfully treated with long-acting octreotide.
Endocr J 2005 Oct;52(5):511-7
6. Postoperative chylous ascites in a neonate treated successfully with octreotide: bile sludge and cholestasis.
Am J Perinatol 2005 Nov;22(8):401-4